Malignant melanomas metastatic to the thyroid gland are uncommon. Based on microscopy and DNA methylation profile, we report a rare coexistence of neoplasms in the thyroid, presumably in our case, with relapse-free condition on adjuvant therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443434 | PMC |
| http://dx.doi.org/10.1002/ccr3.4790 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Behavior of Nasopharynx Malignancies: a Retrospective Study in a Ten-Year Sample.
Neuro Endocrinol Lett
December 2024
Department of Otorhinolaryngology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Czech Republic.
Objectives: Malignant tumors of the nasopharynx make up 3% of malignancies in the ENT area. The most common nasopharyngeal malignancy is nasopharyngeal carcinoma (NPC), followed by lymphomas. Other nasopharyngeal tumors are very rare.
View Article and Find Full Text PDFPrognostic impact of tumor cell nuclear size assessed by artificial intelligence in esophageal squamous cell carcinoma.
Lab Invest
December 2024
Department of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513 Japan.
Tumor cell nuclear size (NS) indicates malignant potential in breast cancer; however, its clinical significance in esophageal squamous cell carcinoma (ESCC) is unknown. Artificial intelligence (AI) can quantitatively evaluate histopathological findings. The aim was to measure NS in ESCC using AI and elucidate its clinical significance.
View Article and Find Full Text PDFThe multiple facets of ovarian high grade serous carcinoma: a review on morphological, immunohistochemical and molecular features.
Crit Rev Oncol Hematol
December 2024
Pathology Unit, Department of Woman and Child's Health and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy; Pathology Institute, Catholic University of Sacred Heart, 00168 Rome, Italy. Electronic address:
High-grade serous ovarian carcinoma (HGSOC) is the most aggressive subtype of epithelial ovarian cancer and a leading cause of mortality among gynecologic malignancies. This review aims to comprehensively analyze the morphological, immunohistochemical, and molecular features of HGSOC, highlighting its pathogenesis and identifying biomarkers with diagnostic, prognostic, and therapeutic significance. Special emphasis is placed on the role of tumor microenvironment (TME) and genomic instability in shaping the tumor's behavior and therapeutic vulnerabilities.
View Article and Find Full Text PDFComparative analysis of combined methylene blue photodynamic therapy and doxorubicin treatment of oral squamous cell carcinoma cell line: in vitro study on apoptosis.
Photodiagnosis Photodyn Ther
December 2024
Dentistry Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Introduction: Squamous cell carcinoma (SCC) is the most common malignancy of the head and neck region. Combination therapy potentially enhances the effectiveness beyond that of each treatment alone. This study aimed to assess whether photodynamic therapy (PDT), using methylene blue as a photosensitizer in conjunction with doxorubicin, produces synergistic effects on the apoptosis of the oral squamous cell carcinoma (OSCC) cell line.
View Article and Find Full Text PDFA rare case of primary chordoma of the nasopharynx mimicking nasopharyngeal carcinoma: A case report.
Int J Surg Case Rep
December 2024
Department of Internal medicine, Hawassa University Comprehensive Specialized Hospital, Hawassa, Sidama, Ethiopia.
Introduction And Importance: Chordoma is an uncommon malignant tumor that originates from the remnants of the primitive notochord in the embryo. They account for 1 % of intracranial tumors and 4 % of primary bone tumors. It is a locally aggressive tumor with a low risk of metastasis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!